Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex dosing by different weight metrics for reversal of neuromuscular block in bariatric surgery
RBR-7ms62xPhase 4Completed
- Sponsor
- Universidade Federal de Pernambuco
- Start
- Jan 2015
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Sugammadex in obesity (3 arms), sponsored by Universidade Federal de Pernambuco. Primary endpoint: Time to reversal of neuromuscular blockade. Started Jan 2015; status: completed.
02
Drugs
Sugammadex
03
Conditions
obesity
Beyond the preview
Go deeper on RBR-7ms62x.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-7ms62x.